Specialty pharmaceutical company Santarus Inc. posted a smaller net loss Nov. 3 helped in part by sales of its heartburn drug Zegerid.
The company reported a net loss of $4 million on revenues of $32.2 million for the third quarter, compared with a net loss of $6.9 million on revenues of $26.5 million during the same period a year ago.
The company also said it expects to break even in the fourth quarter. For the year, it forecast revenues in excess of $125 million, and lowered its net loss guidance.
Shares of Santarus, traded under the symbol SNTS on the Nasdaq, closed up 14 cents at $1.82 Nov. 3.
- Advertisement -
, Heather Chambers
